Drug Profile
LY 3316531
Alternative Names: LY3316531Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antipsoriatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for phase-I development in Psoriasis(In volunteers) in Belgium (IV)
- 28 Feb 2021 No recent reports of development identified for phase-I development in Psoriasis in USA (IV)
- 28 Feb 2021 No recent reports of development identified for phase-I development in Psoriasis in USA (SC)